The Wall Street Journal reports that Pharmacylics today announced that the enrollment target of 350 patients for its Phase III study using ibrutinib monotherapy versus ofatumumab in patients with relapsed or refractory CLL/SLL, has been achieved ahead of schedule and enrollments are now officially closed:
online.wsj.com/article/PR-C...
Good to see patients being thanked too!
It will be interesting to see the outcomes of this larger trial.
Neil
CT scan Boney lesions, I have just had a CT scan and boney lesions have been detected on my pelvis and lower spine, is this CLL related. 
Acalabrutinib, NYU, Columbia Presbyterian, and Dr. Nicole Lamanna
Puzzled
CRAMP
